

8. Shiroshita H, Watanabe H, Ajioka Y, Watanabe G, Nishikura K, Kitano S. Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. *Pathol Int.* 2004;54(5):311–21.
9. Kabashima A, Yao T, Maehara Y, Tsuneyoshi M. Relationship between biological behavior and phenotypic expression in undifferentiated-type gastric carcinomas. *Gastric Cancer.* 2005;8(4):220–7.
10. Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T, Kuwano H. Clinical significance of mucin phenotype, beta-catenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma. *Br J Surg.* 2005;92(4):454–62.
11. Kushima R, Jancic S, Hattori T. Association between expression of sialosyl-Tn antigen and intestinalization of gastric carcinomas. *Int J Cancer.* 1993;55(6):904–8.
12. Yamachika T, Inada K, Fujimitsu Y, Nakamura S, Yamamura Y, Kitou T, et al. Intestinalization of gastric signet ring cell carcinomas with progression. *Virchows Arch.* 1997;431(2):103–10.
13. Aihara R, Mochiki E, Kamiyama Y, Kamimura H, Asao T, Kuwano H. Mucin phenotypic expression in early signet ring cell carcinoma of the stomach: its relationship with the clinicopathologic factors. *Dig Dis Sci.* 2004;49(3):417–24.
14. Bamba M, Sugihara H, Kushima R, Okada K, Tsukashita S, Horinouchi M, et al. Time-dependent expression of intestinal phenotype in signet ring cell carcinomas of the human stomach. *Virchows Arch.* 2001;438(1):49–56.
15. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. *Gastroenterology.* 2000;119(4):961–71.
16. Liu Q, Teh M, Ito K, Shah N, Ito Y, Yeoh KG. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer. *Mod Pathol.* 2007;20(12):1286–97.
17. Mizoshita T, Tsukamoto T, Inada K, Ogasawara N, Hirata A, Kato S, et al. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa. *Pathol Int.* 2004;54(6):392–400.
18. Mizoshita T, Inada K, Tsukamoto T, Nozaki K, Joh T, Itoh M, et al. Expression of the intestine-specific transcription factors, Cdx1 and Cdx2, correlates shift to an intestinal phenotype in gastric cancer cells. *J Cancer Res Clin Oncol.* 2004;130(1):29–36.
19. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. *J Cancer Res Clin Oncol.* 2003;129(12):727–34.
20. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. *Cancer Lett.* 2002;176(1):47–55.
21. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. *J Pathol.* 2003;199(1):36–40.
22. Natsagdorj L, Sugihara H, Bamba M, Hattori T. Intratumoural heterogeneity of intestinal expression reflects environmental induction and progression-related loss of induction in undifferentiated-type gastric carcinomas. *Histopathology.* 2008;53(6):685–97.
23. Tian MM, Zhao AL, Li ZW, Li JY. Phenotypic classification of gastric signet ring cell carcinoma and its relationship with clinicopathologic parameters and prognosis. *World J Gastroenterol.* 2007;13(23):3189–98.
24. Ikeda Y, Mori M, Kamakura T, Haraguchi Y, Saku M, Sugimachi K. Increased incidence of undifferentiated type of gastric cancer with tumor progression in 912 patients with early gastric cancer and 1245 with advanced gastric cancer. *Cancer.* 1994;73(10):2459–63.
25. Endoh Y, Tamura G, Watanabe H, Motoyama T. Author's reply. *J Pathol.* 2000;191(4):467–8.
26. Saito A, Shimoda T, Nakanishi Y, Ochiai A, Toda G. Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. *Pathol Int.* 2001;51(3):165–71.
27. Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. *Cancer.* 2000;89(4):724–32.
28. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer.* 2011;14(2):101–12.
29. Machado JC, Nogueira AM, Carneiro F, Reis CA, Sobrinho-Simoes M. Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). *J Pathol.* 2000;190(4):437–43.
30. Jass JR. Mucin core proteins as differentiation markers in the gastrointestinal tract. *Histopathology.* 2000;37(6):561–4.
31. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. *Pathol Int.* 1997;47(12):813–30.
32. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol.* 1996;20(10):1161–81.
33. Park DY, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. *Mod Pathol.* 2010;23(1):54–61.
34. Nakamura T, Yao T, Kabashima A, Nishiyama K, Maehara Y, Tsuneyoshi M. Loss of phenotypic expression is related to tumour progression in early gastric differentiated adenocarcinoma. *Histopathology.* 2005;47(4):357–67.

# Discrete Nature of EpCAM<sup>+</sup> and CD90<sup>+</sup> Cancer Stem Cells in Human Hepatocellular Carcinoma

Taro Yamashita,<sup>1</sup> Masao Honda,<sup>1</sup> Yasunari Nakamoto,<sup>1</sup> Masayo Baba,<sup>1</sup> Kouki Nio,<sup>1</sup> Yasumasa Hara,<sup>1</sup> Sha Sha Zeng,<sup>1</sup> Takehiro Hayashi,<sup>1</sup> Mitsumasa Kondo,<sup>1</sup> Hajime Takatori,<sup>1</sup> Tatsuya Yamashita,<sup>1</sup> Eishiro Mizukoshi,<sup>1</sup> Hiroko Ikeda,<sup>1</sup> Yoh Zen,<sup>1</sup> Hiroyuki Takamura,<sup>1</sup> Xin Wei Wang,<sup>2</sup> and Shuichi Kaneko<sup>1</sup>

Recent evidence suggests that hepatocellular carcinoma (HCC) is organized by a subset of cells with stem cell features (cancer stem cells; CSCs). CSCs are considered a pivotal target for the eradication of cancer, and liver CSCs have been identified by the use of various stem cell markers. However, little information is known about the expression patterns and characteristics of marker-positive CSCs, hampering the development of personalized CSC-targeted therapy. Here, we show that CSC markers EpCAM and CD90 are independently expressed in liver cancer. In primary HCC, EpCAM<sup>+</sup> and CD90<sup>+</sup> cells resided distinctively, and gene-expression analysis of sorted cells suggested that EpCAM<sup>+</sup> cells had features of epithelial cells, whereas CD90<sup>+</sup> cells had those of vascular endothelial cells. Clinicopathological analysis indicated that the presence of EpCAM<sup>+</sup> cells was associated with poorly differentiated morphology and high serum alpha-fetoprotein (AFP), whereas the presence of CD90<sup>+</sup> cells was associated with a high incidence of distant organ metastasis. Serial xenotransplantation of EpCAM<sup>+</sup>/CD90<sup>+</sup> cells from primary HCCs in immunodeficient mice revealed rapid growth of EpCAM<sup>+</sup> cells in the subcutaneous lesion and a highly metastatic capacity of CD90<sup>+</sup> cells in the lung. In cell lines, CD90<sup>+</sup> cells showed abundant expression of c-Kit and *in vitro* chemosensitivity to imatinib mesylate. Furthermore, CD90<sup>+</sup> cells enhanced the motility of EpCAM<sup>+</sup> cells when cocultured *in vitro* through the activation of transforming growth factor beta (TGF- $\beta$ ) signaling, whereas imatinib mesylate suppressed *TGFBI* expression in CD90<sup>+</sup> cells as well as CD90<sup>+</sup> cell-induced motility of EpCAM<sup>+</sup> cells. **Conclusion:** Our data suggest the discrete nature and potential interaction of EpCAM<sup>+</sup> and CD90<sup>+</sup> CSCs with specific gene-expression patterns and chemosensitivity to molecular targeted therapy. The presence of distinct CSCs may determine the clinical outcome of HCC. (HEPATOLOGY 2013;57:1484-1497)

The cancer stem cell (CSC) hypothesis, which suggests that a subset of cells bearing stem-cell-like features is indispensable for tumor development, has recently been put forward subsequent to advances in molecular and stem cell biology. Liver cancer, including hepatocellular carcinoma

(HCC), is a leading cause of cancer death worldwide.<sup>1</sup> Recent studies have shown the existence of CSCs in liver cancer cell lines and primary HCC specimens using various stem cell markers.<sup>2-7</sup> Independently, we have identified novel HCC subtypes defined by the hepatic stem/progenitor cell markers,

*Abbreviations:* 5-FU, fluorouracil; Abs, antibodies; AFP, alpha-fetoprotein; CK-19, cytokeratin-19; CSC, cancer stem cell; DN, dysplastic nodules; EMT, epithelial mesenchymal transition; EpCAM, epithelial cell adhesion molecule; FACS, fluorescent-activated cell sorting; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HSCs, hepatic stem cells; IF, immunofluorescence; IHC, immunohistochemistry; IR, immunoreactivity; MDS, multidimensional scaling; NBNC, non-B, non-C hepatitis; NOD/SCID, nonobese diabetic, severe combined immunodeficient; NT, nontumor; OV-1, ovalbumin 1; qPCR, quantitative real-time polymerase chain reaction; SC, subcutaneous; Smad3, Mothers against decapentaplegic homolog 3; TECs, tumor epithelial cells; TGF- $\beta$ , transforming growth factor beta; T/N, tumor/nontumor; VECs, vascular endothelial cells; VM, vasculogenic mimicry; VEGFR, vascular endothelial growth factor receptor.

From the <sup>1</sup>Liver Center, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; and <sup>2</sup>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Received July 9, 2012; revised October 22, 2012; accepted November 6, 2012.

This study was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (23590967), a grant from the Japanese Society of Gastroenterology, a grant from the Ministry of Health, Labor, and Welfare, and a grant from the National Cancer Center Research and Development Fund (23-B-5) of Japan. X.W.W. is supported by the Intramural Research Program of the Center for Cancer Research, U.S. National Cancer Institute.

epithelial cell adhesion molecule (EpCAM) and alpha-fetoprotein (AFP), which correlate with distinct gene-expression signatures and prognosis.<sup>8,9</sup> EpCAM<sup>+</sup> HCC cells isolated from primary HCC and cell lines show CSC features, including tumorigenicity, invasiveness, and resistance to fluorouracil (5-FU).<sup>10</sup> Similarly, other groups have shown that CD133<sup>+</sup>, CD90<sup>+</sup>, and CD13<sup>+</sup> HCC cells are also CSCs, and that EpCAM, CD90, and CD133 are the only markers confirmed to enrich CSCs from primary HCCs thus far.<sup>3-5,10</sup>

Although EpCAM<sup>+</sup>, CD90<sup>+</sup>, and CD133<sup>+</sup> cells show CSC features, such as high tumorigenicity, an invasive nature, and resistance to chemo- and radiation therapy, it remains unclear whether these cells represent an identical HCC population and whether they share similar or distinct characteristics. In this study, we used fluorescent-activated cell sorting (FACS), microarray, and immunohistochemistry (IHC) techniques to investigate the expression patterns of the representative liver CSC markers CD133, CD90, and EpCAM in a total of 340 HCC cases and 7 cases of mesenchymal liver tumors. We further explored gene- and protein-expression patterns as well as tumorigenic capacity of sorted cells isolated from 15 primary HCCs and 7 liver cancer cell lines in an attempt to identify the molecular portraits of each cell type.

## Materials and Methods

**Clinical Specimens.** HCC samples were obtained with informed consent from patients who had undergone radical resection at the Liver Center in Kanazawa University Hospital (Kanazawa, Japan), and tissue acquisition procedures were approved by the ethics committee of Kanazawa University. A total of 102 formalin-fixed and paraffin-embedded HCC samples, obtained from 2001 to 2007, were used for IHC analyses. Fifteen fresh HCC samples were obtained between 2008 and 2012 from surgically resected specimens and an autopsy specimen and were used immediately to prepare single-cell suspensions and xenotransplantation (Table 1). Seven hepatic stromal tumors (three cavernous hemangioma, two hemangioendothelioma, and two angiomyolipoma) were formalin fixed and paraffin embedded and used for IHC analyses.

**Table 1. Clinicopathological Characteristics of HCC Cases Used for Xenotransplantation**

ID	Age/ Sex	Etiology	Tumor Size (cm)	Histological Grade	AFP (ng/mL)	DCP (IU/mL)
P1	77/M	Alcohol	12.0	Moderate	198	322
P2	61/F	NBNC	11.0	Moderate	12	3,291
P3	66/M	NBNC	2.2	Moderate	13	45
P4	65/M	HCV	4.2	Poor	13,700	25,977
P5	52/M	HBV	6.0	Moderate	29,830	1,177
P6	60/M	HCV	2.7	Poor	249	185
P7	79/F	HBV	4.0	Poor	46,410	384
P8	77/F	NBNC	5.5	Moderate	17,590	562
P9	71/M	Alcohol	7.0	Poor	3,814	607
P10	51/M	HBV	2.2	Well	<10	21
P11	71/M	Alcohol	2.1	Well	<10	11
P12	60/M	HBV	10.8	Poor	323	2,359
P13	66/M	HCV	2.8	Moderate	11	29
P14	71/M	HCV	7.2	Moderate	235,700	375,080
P15	75/M	HBV	5.5	Poor	<10	97

Abbreviation: DCP, des-gamma-carboxy prothrombin.

Additional details of experimental procedures are available in the Supporting Information.

## Results

**EpCAM, CD133, and CD90 Expression in HCC.** We first evaluated the frequencies of three representative CSC markers (EpCAM<sup>+</sup>, CD90<sup>+</sup>, and CD133<sup>+</sup> cells) in 12 fresh primary HCC cases surgically resected by FACS (representative data shown in Fig. 1A). Clinicopathological characteristics of primary HCC cases are shown in Table 1. We noted that frequency of EpCAM<sup>+</sup>, CD90<sup>+</sup>, and CD133<sup>+</sup> cells varied between individuals. Abundant CD90<sup>+</sup> (7.0%), but almost no EpCAM<sup>+</sup>, cells (0.06%, comparable to the isotype control) were detected in P2, whereas few CD90<sup>+</sup> (0.6%), but abundant EpCAM<sup>+</sup>, cells (17.5%) were detected in P4. Very small populations of EpCAM<sup>+</sup> (0.09%), CD90<sup>+</sup> (0.04%), and CD133<sup>+</sup> cells (0.05%) were found in P12, but they were almost nonexistent in P8, except for CD90<sup>+</sup> cells (0.08%) (Fig. 1A). We further evaluated the expression of EpCAM, CD90, and CD133 in xenografts obtained from surgically resected samples (P13 and P15) and an autopsy sample (P14). As a whole, compared to the isotype control, 7 of 15 HCCs contained definite EpCAM<sup>+</sup> cells (46.7%), whereas only 3 HCCs

Address reprint requests to: Taro Yamashita, M.D., Ph.D., Department of General Medicine, Kanazawa University Hospital, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan. E-mail: taroy@m-kanazawa.jp; fax: +81-76-234-4250.

Copyright © 2013 by the American Association for the Study of Liver Diseases.

View this article online at wileyonlinelibrary.com.

DOI 10.1002/hep.26168

Potential conflict of interest: Nothing to report.

Additional Supporting Information may be found in the online version of this article.




Fig. 1. Gene-expression profiles of CSC marker-positive HCCs. (A) FACS analysis of primary HCCs stained with fluorescent-labeled Abs against EpCAM, CD90, or CD133. (B) Multidimensional scaling analysis of 172 HCC cases characterized by the expression patterns of EpCAM, CD133, and CD90. Red, EpCAM<sup>+</sup> CD90<sup>-</sup> CD133<sup>-</sup> (n = 34); orange, EpCAM<sup>-</sup> CD90<sup>-</sup> CD133<sup>+</sup> (n = 10); light blue, EpCAM<sup>-</sup> CD90<sup>+</sup> CD133<sup>-</sup> (n = 49); blue, EpCAM<sup>-</sup> CD90<sup>-</sup> CD133<sup>-</sup> (n = 79). HCC specimens were clustered in specific groups with statistical significance ( $P < 0.001$ ). (C) Expression patterns of well-known hepatic stem/progenitor markers in each HCC subtype, as analyzed by microarray. Red bar, EpCAM<sup>+</sup>; orange bar, CD133<sup>+</sup>; light blue bar, CD90<sup>+</sup>; blue bar, EpCAM<sup>-</sup> CD90<sup>-</sup> CD133<sup>-</sup>. (D) Hierarchical cluster analysis based on 1,561 EpCAM/CD90/CD133-coregulated genes in 172 HCC cases. Each cell in the matrix represents the expression level of a gene in an individual sample. Red and green cells depict high and low expression levels, respectively, as indicated by the scale bar. (E) Pathway analysis of EpCAM/CD90/CD133-coregulated genes. Canonical signaling pathways activated in cluster A (red bar), cluster B (orange bar), or cluster C (light blue bar) with statistical significance ( $P < 0.01$ ) are shown. (F) Expression patterns of representative genes differentially expressed in EpCAM/CD90/CD133 HCC subtypes. Red bar, EpCAM<sup>+</sup>; orange bar, CD133<sup>+</sup>; light blue bar, CD90<sup>+</sup>; blue bar, EpCAM<sup>-</sup> CD133<sup>-</sup> CD90<sup>-</sup>.

**Table 2. Tumorigenic Capacity of Unsorted, EpCAM<sup>+</sup>, EpCAM<sup>-</sup>, CD90<sup>+</sup>, and CD90<sup>-</sup> Cells From Primary HCCs and Xenografts**

Sample	CD133 (%)	CD90 (%)	EpCAM (%)	Cell Surface Marker	Number of Cells	Tumor Formation	
						2M	3M
P1	0	3.1	0	Unsorted	1 × 10 <sup>7</sup>	0/5	0/5
				CD90 <sup>+</sup>	1 × 10 <sup>5</sup>	0/5	0/5
				CD90 <sup>-</sup>	1 × 10 <sup>5</sup>	0/5	0/5
P2	0.06	7.0	0.06	Unsorted	1 × 10 <sup>7</sup>	0/5	0/5
				CD90 <sup>+</sup>	1 × 10 <sup>5</sup>	0/5	0/5
				CD90 <sup>-</sup>	1 × 10 <sup>5</sup>	0/5	0/5
P3	0	1.3	0	Unsorted	1 × 10 <sup>6</sup>	0/2	0/2
				CD90 <sup>+</sup>	1 × 10 <sup>4</sup>	0/4	0/4
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/4	0/4
P4	0	0.6	17.5	Unsorted	1 × 10 <sup>6</sup>	3/4	4/4
				EpCAM <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	2/3
					1 × 10 <sup>4</sup>	3/4	4/4
					1 × 10 <sup>5</sup>	3/3	3/3
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
					1 × 10 <sup>4</sup>	0/4	0/4
					1 × 10 <sup>5</sup>	0/3	0/3
				EpCAM <sup>-</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/4	0/4
					1 × 10 <sup>5</sup>	0/3	0/3
P5	0	0.8	29.7	Unsorted	1 × 10 <sup>6</sup>	0/5	0/5
				EpCAM <sup>+</sup>	1 × 10 <sup>5</sup>	0/5	0/5
				CD90 <sup>+</sup>	1 × 10 <sup>5</sup>	0/5	0/5
				EpCAM <sup>-</sup>	1 × 10 <sup>5</sup>	0/5	0/5
P6	0	0.7	0	Unsorted	1 × 10 <sup>6</sup>	0/2	0/2
				CD90 <sup>+</sup>	1 × 10 <sup>4</sup>	0/4	0/4
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/4	0/4
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/4	0/4
P7	1.38	4.5	4.4	Unsorted	1 × 10 <sup>6</sup>	2/2	2/2
				EpCAM <sup>+</sup>	2 × 10 <sup>2</sup>	0/3	0/3
					1 × 10 <sup>3</sup>	0/3	1/3
					1 × 10 <sup>4</sup>	2/4	4/4
				CD90 <sup>+</sup>	2 × 10 <sup>2</sup>	0/3	0/3
					1 × 10 <sup>3</sup>	0/3	0/3
					1 × 10 <sup>4</sup>	0/4	0/4
P8	0	0.08	0	Unsorted	1 × 10 <sup>5</sup>	0/4	0/4
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				CD90 <sup>-</sup>	1 × 10 <sup>5</sup>	0/3	0/3
				CD90 <sup>-</sup>	1 × 10 <sup>5</sup>	0/3	0/3
P9	0	0.26	0	Unsorted	1 × 10 <sup>5</sup>	0/4	0/4
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				CD90 <sup>-</sup>	1 × 10 <sup>5</sup>	0/3	0/3
P10	0	0.78	0	Unsorted	1 × 10 <sup>4</sup>	0/4	0/4
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/3	0/3
P11	0	0.1	1.54	Unsorted	5 × 10 <sup>4</sup>	0/2	0/2
				EpCAM <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/3	0/3
				EpCAM <sup>-</sup>	1 × 10 <sup>4</sup>	0/3	0/3
P12	0.06	0.05	0.09	Unsorted	1 × 10 <sup>5</sup>	0/3	3/3
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/4	1/4
				CD90 <sup>+</sup>	1 × 10 <sup>3</sup>	0/4	1/4
				CD90 <sup>-</sup>	1 × 10 <sup>4</sup>	0/3	3/3

(Continued)

**TABLE 2. (Continued)**

Sample	CD133 (%)	CD90 (%)	EpCAM (%)	Cell Surface Marker	Number of Cells	Tumor Formation	
						2M	3M
P13	0	0.03	67.7	EpCAM <sup>+</sup>	5 × 10 <sup>5</sup>	4/4	NA
					5 × 10 <sup>4</sup>	3/3	NA
					5 × 10 <sup>3</sup>	3/3	NA
				EpCAM <sup>-</sup>	5 × 10 <sup>5</sup>	0/4	NA
					5 × 10 <sup>4</sup>	0/3	NA
P14	24.0	0.06	3.1	EpCAM <sup>+</sup>	5 × 10 <sup>3</sup>	4/5	NA
					5 × 10 <sup>3</sup>	2/5	NA
				EpCAM <sup>-</sup>	5 × 10 <sup>3</sup>	0/3	NA
					5 × 10 <sup>3</sup>	0/3	NA
				CD90 <sup>+</sup>	5 × 10 <sup>4</sup>	3/4	NA
P15	0	2.45	0	CD90 <sup>+</sup>	5 × 10 <sup>4</sup>	1/3	NA
					5 × 10 <sup>3</sup>	1/3	NA
					5 × 10 <sup>2</sup>	1/3	NA
				CD90 <sup>-</sup>	5 × 10 <sup>4</sup>	2/4	NA
					5 × 10 <sup>3</sup>	1/3	NA
	5 × 10 <sup>2</sup>	0/3	NA				

NA, not available.

contained definite CD133<sup>+</sup> cells (20%) (Table 2). CD90<sup>+</sup> cells were detected at variable frequencies in all 15 HCCs analyzed.

To explore the status of these CSC marker-positive cells in HCC in a large cohort, we utilized oligo-DNA microarray data from 238 HCC cases (GEO accession no.: GSE5975) to evaluate the expression of *EPCAM* (encoding EpCAM and CD326), *THY1* (encoding CD90), and *PROM1* (encoding CD133) in whole HCC tissues and nontumor (NT) tissues. Because previous studies demonstrated that CD133<sup>+</sup> and CD90<sup>+</sup> cells were detected at low frequency (~13.6% by CD133 staining and ~6.2% by CD90 staining) in HCC, but were almost nonexistent in NT liver (4, 5),<sup>4,5</sup> we utilized tumor/nontumor (T/N) gene-expression ratios to detect the existence of marker-positive CSCs in tumor. Accordingly, we showed that a 2-fold cutoff of T/N ratios of *EPCAM* successfully stratifies HCC samples with EpCAM<sup>+</sup> liver CSCs.<sup>9,10</sup>

A total of 95 (39.9%), 110 (46.2%), and 31 (13.0%) of the 238 HCC cases were thus regarded as EpCAM<sup>+</sup>, CD90<sup>+</sup>, and CD133<sup>+</sup> HCCs (T/N ratios: ≥2.0), respectively. As observed in the FACS data described above, we detected coexpression of EpCAM and CD90 in 45 HCCs (18.9%), EpCAM and CD133 in five HCCs (2%), CD90 and CD133 in five HCCs (2%), and EpCAM, CD90, and CD133 in 11 HCCs (4.6%). To clarify the characteristics of gene-expression signatures specific to stem cell marker expression status, we selected 172 HCC cases expressing a single CSC marker (34 EpCAM<sup>+</sup> CD90<sup>-</sup> CD133<sup>-</sup>, 49 EpCAM<sup>-</sup> CD90<sup>+</sup> CD133<sup>-</sup>, and 10 EpCAM<sup>-</sup> CD90<sup>-</sup> CD133<sup>+</sup>) or all marker-negative HCCs (79 EpCAM<sup>-</sup> CD90<sup>-</sup> CD133<sup>-</sup>). A class-comparison analysis with

univariate F tests and a global permutation test ( $\times 10,000$ ) yielded a total of 1,561 differentially expressed genes. Multidimensional scaling (MDS) analysis using this gene set indicated that HCC specimens were clustered in specific groups with statistical significance ( $P < 0.001$ ). Close examination of MDS plots revealed three major HCC subtype clusters: all marker-negative HCCs (blue spheres); EpCAM single-positive HCCs (red spheres); and CD90 single-positive HCCs (light blue spheres). CD133<sup>+</sup> HCCs (orange spheres) were rare, relatively scattered, and not clustered (Fig. 1B).

We examined the expression of representative hepatic stem/progenitor cell markers *AFP*, *KRT19*, and *DLK1* in HCCs with regard to the gene-expression status of each CSC marker (Fig. 1C). All three markers were up-regulated in EpCAM<sup>+</sup> and CD133<sup>+</sup> HCCs, compared with all marker-negative HCCs, consistent with previous findings.<sup>10,11</sup> However, we found no significant overexpression of *AFP*, *KRT19*, and *DLK1* in CD90<sup>+</sup> and all marker-negative HCCs.

Hierarchical cluster analyses revealed three main gene clusters that were up-regulated in EpCAM<sup>+</sup> HCCs (cluster A, 706 genes), EpCAM<sup>+</sup> or CD133<sup>+</sup> HCCs (cluster B, 530 genes), and CD90<sup>+</sup> or CD133<sup>+</sup> HCCs (cluster C, 325 genes) (Fig. 1D). Pathway analysis indicated that the enriched genes in cluster A (red bar) were associated with chromatin modification, cell-cycle regulation, and Wnt/ $\beta$ -catenin signaling (Fig. 1E). Genes associated with messenger RNA processing were enriched in clusters A (red bar) and B (orange bar). Surprisingly, genes in cluster C were significantly associated with pathways involved in blood-vessel morphogenesis, angiogenesis, neurogenesis, and epithelial mesenchymal transition (EMT) (light blue bar). Close examination of genes in each cluster suggested that known hepatic transcription factors (*FOXA1*), Wnt regulators (*TCF7L2* and *DKK1*), and a hepatic stem cell marker (*CD24*) were dominantly up-regulated in EpCAM<sup>+</sup> and CD133<sup>+</sup> HCCs (Fig. 1F). By contrast, genes associated with blood-vessel morphogenesis (*TIE1* and *FLT1*), EMT (*TGFB1*), and neurogenesis (*NES*) were activated dominantly in CD90<sup>+</sup> HCCs and CD133<sup>+</sup> HCCs.

**CD90<sup>+</sup> HCC Cells Share Features With Mesenchymal Vascular Endothelial Cells.** Because CD133<sup>+</sup> HCCs were relatively rare and constituted only 13% (microarray cohort) to 20% (FACS cohort) of all HCC samples analyzed, we focused on the characterization of EpCAM and CD90. To clarify the cell identity of EpCAM<sup>+</sup> or CD90<sup>+</sup> cells in primary HCCs, we performed IHC analysis of 18 needle-biopsy

specimens of premalignant dysplastic nodules (DNs), 102 surgically resected HCCs, and corresponding NT liver tissues. When examining the expression of EpCAM and CD90 in cirrhotic liver tissue by double-color IHC analysis, we found that EpCAM<sup>+</sup> cells and CD90<sup>+</sup> cells were distinctively located and not colocalized (Supporting Fig. 1A). Immunoreactivity (IR) to anti-CD90 antibodies (Abs) was detected in vascular endothelial cells (VECs), inflammatory cells, fibroblasts, and neurons, but not in hepatocytes or cholangiocytes, in the cirrhotic liver (Supporting Fig. 1B, panels a,b). IR to anti-EpCAM Abs was detected in hepatic progenitors adjacent to the periportal area and bile duct epithelial cells in liver cirrhosis (Supporting Fig. 1B, panels c,d).

IR to anti-EpCAM Abs was detected in 37 of 102 surgically resected HCCs (Fig. 2A, panel b), but not in 18 DN (Fig. 2A, panel a). By contrast, no tumor epithelial cells (TECs) showing IR to anti-CD90 Abs were found in any of the 18 DN or 102 HCCs examined (Fig. 2A, panels c,d). However, we identified CD90<sup>+</sup> cells that were morphologically similar to VECs or fibroblasts within the tumor nodule in 37 of the 102 surgically resected HCC tissues ( $\geq 5\%$  positive staining in a given area). IR to anti-CD90 Abs was also detected in hepatic mesenchymal tumors (Supporting Fig. 1C, panels a-c), indicating that CD90 is also a marker of liver stromal tumors.

Double-color IHC and immunofluorescence (IF) analysis confirmed the distinct expression of EpCAM and CD90 in HCC (Fig. 2B), consistent with the FACS data (Fig. 1A). Quantitative real-time polymerase chain reaction (qPCR) analysis of sorted EpCAM<sup>+</sup>, CD90<sup>+</sup>, and EpCAM<sup>-</sup> CD90<sup>-</sup> cells after CD45<sup>+</sup> cell depletion indicated that the hepatic stem/progenitor markers, *AFP* and *KRT19*, were up-regulated in EpCAM<sup>+</sup> cells (red bar), whereas the mesenchymal markers, *KIT* and *FLT1*, were up-regulated in CD90<sup>+</sup> cells (orange bar), compared with EpCAM<sup>-</sup> CD90<sup>-</sup> cells (blue bar) (Fig. 2C). The hepatocyte marker, *CYP3A4*, was down-regulated in EpCAM<sup>+</sup> cells and not detected in CD90<sup>+</sup> cells, compared with EpCAM<sup>-</sup> CD90<sup>-</sup> cells. *POU5F1* and *BMI1* were equally up-regulated in both EpCAM<sup>+</sup> and CD90<sup>+</sup> cells, compared with EpCAM<sup>-</sup> CD90<sup>-</sup> cells.

EpCAM and CD90 were independently and distinctively expressed in different cellular lineages, so we evaluated the staining of EpCAM and CD90 separately and analyzed the clinicopathological characteristics of surgically resected HCC cases. HCCs were regarded marker positive if  $\geq 5\%$  positive staining was detected in a given area. The existence of EpCAM<sup>+</sup>




Fig. 2. Distinct EpCAM<sup>+</sup> and CD90<sup>+</sup> cell populations in HCC. (A) Representative images of EpCAM and CD90 staining in dysplastic nodule (panels a,c) and HCC (panels b,d) by IHC analysis (scale bar, 50  $\mu$ m). EpCAM (panels a,b) and CD90 (panels c,d) immunostaining is depicted. (B) Upper panel: representative images of EpCAM (red) and CD90 (brown) double staining in HCC by IHC (scale bar, 50  $\mu$ m). Lower panel: representative images of EpCAM (green) and CD90 (red) staining with 4'6-diamidino-phenylindole (DAPI) (blue) in HCC by IF (scale bar, 50  $\mu$ m). (C) qPCR analysis of sorted EpCAM<sup>+</sup> (red bar), CD90<sup>+</sup> (orange bar), or EpCAM<sup>-</sup>CD90<sup>-</sup> (blue bar) derived from a representative primary HCC. Experiments were performed in triplicate, and data are shown as mean  $\pm$  standard error of the mean.

cells ( $\geq 5\%$ ) was characterized by poorly differentiated morphology and high serum AFP values with a tendency for portal vein invasion, whereas the existence of CD90<sup>+</sup> cells ( $\geq 5\%$ ) was associated with poorly differentiated morphology and a tendency for large tumor size (Supporting Tables 2 and 3). Notably, the existence of CD90<sup>+</sup> cells was associated with a high incidence of distant organ metastasis, including lung, bone, and adrenal gland, within 2 years after surgery, whereas EpCAM<sup>+</sup> cell abundance appeared unrelated to distant organ metastasis.

We evaluated the characteristics of EpCAM<sup>+</sup> or CD90<sup>+</sup> cells in seven representative HCC cell lines. Morphologically, all EpCAM<sup>+</sup> cell lines (HuH1, HuH7, and Hep3B) showed a polygonal, epithelial cell shape, whereas three of four CD90<sup>+</sup> cell lines (HLE, HLF, and SK-Hep-1) showed a spindle cell shape (Fig. 3A). EpCAM<sup>+</sup> cells were detected in 11.5%, 57.7%, and 99.6% of sorted HuH1, HuH7,

and Hep3B cells, respectively. A small CD90<sup>+</sup> cell population (0.66%) was observed in PLC/PRL/5, whereas 91.3%, 10.8%, and 59.0% of CD90<sup>+</sup> cells were detected in HLE, HLF, and SK-Hep-1, respectively. Compared with primary HCCs, only EpCAM<sup>+</sup> or CD90<sup>+</sup> cells were detected in liver cancer cell lines under normal culture conditions (Fig. 3B), suggesting that these cell lines contain a relatively pure cell population most likely obtained by clonal selection through the establishment process.

A class-comparison analysis with univariate *t* tests and a global permutation test ( $\times 10,000$ ) of microarray data yielded two main gene clusters up-regulated in EpCAM<sup>+</sup> cell lines (HuH1, HuH7, and Hep3B) (cluster I, 524 genes) or in CD90<sup>+</sup> cell lines (HLE, HLF, and SK-Hep-1) (cluster II, 366 genes) (Fig. 3C). PLC/PRL/5 showed intermediate gene-expression patterns between EpCAM<sup>+</sup> and CD90<sup>+</sup> cell lines using this gene set. Pathway analysis indicated that the genes




Fig. 3. Characteristics of HCC cell lines defined by EpCAM and CD90. (A) Representative photomicrographs of EpCAM<sup>+</sup>CD90<sup>-</sup> and EpCAM<sup>-</sup>CD90<sup>+</sup> HCC cell lines. (B) Representative FACS data of EpCAM<sup>+</sup>CD90<sup>-</sup> and EpCAM<sup>-</sup>CD90<sup>+</sup> HCC cell lines stained with fluorescein isothiocyanate (FITC)-EpCAM and APC-CD90 Abs. (C) Heat-map images of seven HCC cell lines based on 890 EpCAM/CD90-coregulated genes. Each cell in the matrix represents the expression level of a gene in an individual sample. Red and green cells depict high and low expression levels, respectively, as indicated by the scale bar. (D and E) Pathway analysis of EpCAM/CD90-coregulated genes. Canonical signaling pathways activated in cluster I (orange bar) or II (blue bar) with statistical significance ( $P < 0.01$ ) are shown. (F) qPCR of representative differentially expressed genes identified by microarray analysis (C) in seven HCC cell lines.



enriched in cluster II were mainly associated with blood-vessel morpho- and angiogenesis (Fig. 3D). By contrast, the enriched genes in cluster I were significantly associated with known hepatocyte functions ( $P < 0.01$ ) (Fig. 3E). In addition, we identified that the enriched genes in cluster II were significantly associated with neurogenesis, skeletal muscle development, and EMT.

We used qPCR to validate that known hepatic stem cell (HSC) and hepatocyte markers, such as *AFP*, *EPCAM*, *ALB*, and *HNF4A* genes, were up-regulated in EpCAM<sup>+</sup> cell lines, but not detected in CD90<sup>+</sup> cell lines (Fig. 3F). By contrast, genes associated with mesenchymal lineages and EMT, such as *KIT*, *TWIST1*, *CD44*, and *THY1*, were strongly up-regulated in CD90<sup>+</sup> cell lines.

**Unique Tumorigenicity and Metastasis Capacity of Distinct CSCs Defined by EpCAM and CD90.** We investigated the tumorigenic capacity of EpCAM<sup>+</sup> or CD90<sup>+</sup> cells by subcutaneously (SC) injecting  $1 \times 10^5$  sorted cells of four HCC cell lines (HuH1, HuH7, HLE, and HLF) into nonobese diabetic, severe combined immunodeficient (NOD/SCID) mice. We excluded Hep3B cells for the evaluation of tumorigenicity because almost 100% of cells were EpCAM positive. We further excluded SK-Hep-1 cells from the analysis because they potentially originated from endothelial cells.<sup>12</sup> The highly tumorigenic capacities of EpCAM<sup>+</sup> and CD90<sup>+</sup> cells were reproduced in HuH1, HuH7, and HLF cell lines, compared with marker-negative cells (Fig. 4A). However, HLE cells did not produce SC tumors, even 12 months after transplantation, in NOD/SCID mice. EpCAM<sup>+</sup> cells from HuH1 and HuH7 formed larger tumors more rapidly than CD90<sup>+</sup> cells from HLF (Fig. 4B). IHC analyses indicated that EpCAM<sup>+</sup> cells did not produce CD90<sup>+</sup> cells and *vice versa* in these cell lines *in vivo* (Fig. 4C). CD90<sup>+</sup> cells showed a high metastatic capacity, whereas EpCAM<sup>+</sup> cells showed no metastasis to the lung when SC tumor volume reached approximately 2,000 (HuH1 and HuH7) or 700 mm<sup>3</sup> (HLF) (Fig. 4D). The high metastatic capacity of PLC/PRL/5 cells, which contain a small population of CD90<sup>+</sup> cells, was also confirmed after SC injection into NOD/SCID mice (data not shown). CD90<sup>+</sup> cells could divide to generate both CD90<sup>+</sup> and CD90<sup>-</sup> cells, and CD90<sup>+</sup> cells showed a high capacity to invade and form spheroids with overexpression of *TWIST1* and *TWIST2*, which are known to activate EMT programs in HLF cells (Supporting Fig. 2A-D).

We next evaluated the tumorigenic/metastatic capacity of CD45<sup>-</sup> tumor cells using 12 fresh primary

HCC specimens (P1-P12) that had been surgically resected (Table 2). We further evaluated the tumorigenicity of EpCAM/CD90 sorted cells obtained from xenografts derived from primary HCCs (Supporting Fig. 3A). Of these, we confirmed the tumorigenicity of cancer cells obtained from six primary HCCs after SC injection into NOD/SCID mice within 3 months after transplantation (Fig. 5A; Table 2; Supporting Fig. 3B). EpCAM<sup>+</sup> cells derived from four HCCs (P4, P7, P13, and P14) showed highly tumorigenic capacities, compared with EpCAM<sup>-</sup> cells. CD90<sup>+</sup> cells derived from two HCCs showed equal (P12) or more-tumorigenic capacities (P15), compared with CD90<sup>-</sup> cells. Tumorigenicity of EpCAM<sup>+</sup> cells was observed in three hepatitis C virus (HCV)-related HCCs and an hepatitis B virus (HBV)-related HCC, whereas tumorigenicity of CD90<sup>+</sup> cells was observed in two HBV-related HCCs (Tables 1 and 2).

Using unsorted cells, we compared the frequency of EpCAM<sup>+</sup> and CD90<sup>+</sup> cells in primary and xenograft tumors and found that EpCAM<sup>+</sup> cells remained, but CD90<sup>+</sup> cells disappeared, in secondary tumors derived from P4 or P7, whereas EpCAM<sup>+</sup> cells disappeared, but CD90<sup>+</sup> cells remained, in secondary tumors derived from P12 (Fig. 5B). Morphologically, tumorigenic EpCAM<sup>+</sup> cells showed an epithelial cell shape, whereas CD90<sup>+</sup> cells showed a mesenchymal VEC shape (Fig. 5C and Supporting Fig. 3C). FACS analysis indicated that P12 HCC cells showed abundant expression of vascular endothelial growth factor receptor (VEGFR) 1 and a vascular endothelial marker endoglin (CD105) (Fig. 5D). By contrast, P4 and P7 HCC cells did not express these vascular endothelial markers (data not shown). Lung metastasis was detected in NOD/SCID mice transplanted with P12 HCC cells, but not in mice transplanted with P4 and P7 HCC cells (Fig. 5E,F).

Taken together, these results suggest that the tumorigenic and metastatic capability of primary HCC may depend on the presence of distinct EpCAM<sup>+</sup> or CD90<sup>+</sup> CSCs. EpCAM<sup>+</sup> cells were associated with a high tumorigenic capacity with hepatic epithelial stem cell features, whereas CD90<sup>+</sup> cells were related to the metastatic propensity with VEC features.

**Suppression of Lung Metastasis Mediated by CD90<sup>+</sup> CSCs by Imatinib Mesylate.** We previously demonstrated that Wnt/ $\beta$ -catenin signaling inhibitors could successfully attenuate the tumorigenic capacity of EpCAM<sup>+</sup> CSCs in HCC.<sup>8,10</sup> To explore the potential molecular targets activated in CD90<sup>+</sup> CSCs, we investigated the expression of the known VEC markers, CD105, VEGFR1 (encoded by *FLT1*), and




Fig. 4. Distinct tumorigenic/metastatic capacities of HCC cell lines defined by EpCAM and CD90. (A) Tumorigenicity of  $1 \times 10^5$  cells sorted by anti-EpCAM (HuH1 and HuH7) or anti-CD90 (HLE and HLF) Abs. Data are generated from 8 mice/cell line. (B) Tumorigenic ability of EpCAM<sup>+</sup> and CD90<sup>+</sup> sorted cells in NOD/SCID mice. Aggressive tumor growth in the SC lesion was observed in EpCAM<sup>+</sup> HuH1 or HuH7 cells, compared with CD90<sup>+</sup> HLE or HLF cells. EpCAM<sup>+</sup> ( $1 \times 10^5$ ) or CD90<sup>+</sup> cells were injected. Tumor-volume curves are depicted as mean  $\pm$  standard deviation of 4 mice/group. (C) Histological analysis of EpCAM<sup>+</sup> or CD90<sup>+</sup> cell-derived xenografts. Hematoxylin and eosin (H&E) staining of a SC tumor (upper panels) and IHC of the tumor with anti-EpCAM (middle panels) and anti-CD90 Abs (bottom panels) are shown (scale bar, 50  $\mu$ m). (D) Metastasis was evaluated macroscopically and microscopically in the left and right lobes of the lung separately in each mouse (n = 4) (scale bar, 100  $\mu$ m).

c-Kit (encoded by *KIT*), in cell lines and showed that they were abundantly expressed in CD90<sup>+</sup> cell lines, but not EpCAM<sup>+</sup> cell lines (Fig. 6A). No expression of VEGFR2 was detected in this set of cell lines, suggesting that molecular reagents specifically targeting VEGFR2 may have no effects on CD90<sup>+</sup> CSCs. CD44, a stem cell marker that functionally regulates redox status and is a potential target of CD90<sup>+</sup> CSCs, was also abundantly expressed in CD90<sup>+</sup> cell lines (Supporting Fig. 4A), consistent with previous data.<sup>5,13</sup> No significant difference was detected in the

expression of the hematopoietic marker, CD34, or ABCG2 between EpCAM<sup>+</sup> and CD90<sup>+</sup> cell lines (Supporting Fig. 4A).

Among these molecular targets, we focused on the characterization of c-Kit because the c-Kit tyrosine kinase inhibitor, imatinib mesylate, is readily available, is widely used for the treatment of gastrointestinal stromal tumor with activation of c-Kit, and may have potential antitumor activity against a subset of HCC.<sup>14</sup> We explored the effect of imatinib mesylate on HCC cell lines and found that treatment with 10




Fig. 5. Tumorigenic/metastatic capacities of EpCAM<sup>+</sup> and CD90<sup>+</sup> cells in primary HCC. (A) Representative NOD/SCID mice with SC tumors (white arrows) from EpCAM<sup>+</sup> P4 or P7 cells (left and middle panels) and CD90<sup>+</sup> or CD90<sup>-</sup> P12 cells (right panel). (B) FACS analysis of CD90 and EpCAM staining in primary HCCs and the corresponding secondary tumors developed in NOD/SCID mice. Unsorted cells ( $1 \times 10^6$  cells in P4 and P7 or  $1 \times 10^5$  cells in P12) were SC injected to evaluate the frequency of each marker-positive cell in primary and secondary tumors. (C) IHC analysis of EpCAM and CD90 in primary HCCs P4, P7, and P12 (scale bar, 50  $\mu$ m). (D) FACS analysis of VEGFR1 (Alexa488) and CD105 (APC) in primary HCC P12. (E) Hematoxylin and eosin staining of lung tissues in P4 and P12 (scale bar, 200  $\mu$ m). (F) Frequency of lung metastasis in NOD/SCID mice SC transplanted using unsorted primary HCC cells.

$\mu$ M reduced cell proliferation and spheroid formation in CD90<sup>+</sup> cell lines, but had no effect on EpCAM<sup>+</sup> cell lines (Supporting Fig. S4B,C).

We further explored the effect of imatinib mesylate *in vivo*. Because EpCAM<sup>+</sup> and CD90<sup>+</sup> cells reside in the

primary HCC, but not in established cell lines, we SC injected HuH7 and HLF cell lines to generate tumors organized by EpCAM<sup>+</sup> and CD90<sup>+</sup> CSCs. Interestingly, when HLF cells were coinjected with HuH7 cells, EpCAM<sup>+</sup> cells could metastasize to the lung, whereas









Fig. 6.

SC primary tumors showed no difference in size (Fig. 6B,C). Furthermore, although imatinib mesylate treatment had little effect on the size of primary SC tumors, it significantly suppressed lung metastasis in primary tumors (Fig. 6C). These data suggest that CD90<sup>+</sup> cells are not only metastatic to the distant organ, but also help the metastasis of CD90<sup>-</sup> cells, including EpCAM<sup>+</sup> cells, which originally have no distant metastatic capacity. Our data further suggest that imatinib mesylate can inhibit distant organ metastasis by suppressing CD90<sup>+</sup> metastatic CSCs, albeit with little effect on EpCAM<sup>+</sup> tumorigenic epithelial stem-like CSCs.

To explore the potential mechanism of how CD90<sup>+</sup> cells dictate the metastasis of EpCAM<sup>+</sup> cells, we utilized coculture systems and time-lapse image analysis. Wound-healing analysis clearly indicated that motility of HuH7 cells was enhanced when HLF cells were cocultured, and this effect was abolished by imatinib mesylate treatment (Fig. 6D; see Supporting Videos 1-3). HLF cells abundantly expressed *TGFBI*, compared with HuH7 cells, and its expression was dramatically suppressed by imatinib mesylate treatment (Fig. 6E). Mothers against decapentaplegic homolog 3 (Smad3) phosphorylation was augmented in HuH7 cells when cocultured with HLF cells, and this effect was attenuated when cocultured with HLF cells pretreated with imatinib mesylate.

Taken together, our data suggest that liver CSCs are not a single entity. Liver CSCs defined by different markers show unique features of tumorigenicity/metastasis with phenotypes closely associated with committed liver lineages. These distinct CSCs may collaborate to enhance tumorigenicity and metastasis of HCCs.

## Discussion

The current investigation demonstrates that CSC marker expression status may be a key determinant of cancer phenotypes, in terms of metastatic propensity

and chemosensitivity, to certain molecularly targeted therapies. EpCAM appears to be an epithelial tumorigenic CSC marker, whereas CD90 seems to be a mesenchymal metastatic CSC marker associated with expression of c-Kit and chemosensitivity to imatinib mesylate. Imatinib mesylate may be effective in inhibiting metastasis, but has little effect on primary EpCAM<sup>+</sup> HCC cell growth.

We investigated the frequency of three CSC markers (EpCAM, CD90, and CD133) in 15 primary HCCs with a confirmed cell viability of  $\geq 70\%$  and found that three HCCs contained CD133<sup>+</sup> cells, seven HCCs contained EpCAM<sup>+</sup> cells, and all HCCs contained CD90<sup>+</sup> cells. Among them, we confirmed the perpetuation of CD133<sup>+</sup> cells derived from three HCCs (P7, P12, and P14; data not shown), EpCAM<sup>+</sup> cells derived from four HCCs (P4, P7, P13, and P14), and CD90<sup>+</sup> cells derived from two HCCs (P12 and P15). Recent studies showed that at least 8 of 21 HCCs (38%)<sup>4</sup> and 13 of 13 HCCs (100%)<sup>5</sup> contained tumorigenic CD133<sup>+</sup> or CD90<sup>+</sup> CSCs, respectively. Recent IHC and tissue microarray studies also demonstrated that CD133<sup>+</sup> and CD90<sup>+</sup> cells were detected in 24.8% ( $\geq 1\%$  of tumor cells) and 32.2% ( $\geq 5\%$  of tumor cells) of HCC cases examined, respectively.<sup>15,16</sup>

One possible explanation of the comparatively low frequency of CD133<sup>+</sup> liver CSCs identified in our study is that we used the monoclonal Ab CD133/2, whereas Ma et al. used CD133/1. Another possible explanation is the difference of etiology related to hepatocarcinogenesis. We examined tumorigenicity using 15 HCCs (five HBV related, four HCV related, three non-B, non-C hepatitis [NBNC] related, and three alcohol related) and identified that tumorigenic CSCs were only obtained from HBV- or HCV-related cases. Previous liver CSC studies were performed using HBV-related HCCs,<sup>4,5</sup> and a recent study showed that

Fig. 6. Suppression of lung metastasis mediated by CD90<sup>+</sup> CSCs by imatinib mesylate. (A) FACS analysis of seven HCC cell lines stained by APC-CD105, Alexa 488/VEGFR1, APC/VEGFR2, and Alexa 488/c-Kit Abs or isotype control. (B) Tumorigenicity of  $5 \times 10^5$  HuH7 cells and  $2.5 \times 10^5$  HuH7 cells plus  $2.5 \times 10^5$  HLF cells treated with imatinib mesylate or control phosphate-buffered saline (PBS) (200  $\mu$ L/mouse) orally ingested three times per week (100 mg/kg) for 2 weeks. Data are generated from 5 mice per condition. (C) IHC analysis of EpCAM in lung metastasis detected in NOD/SCID mice SC injected with  $2.5 \times 10^5$  HuH7 cells and  $2.5 \times 10^5$  HLF cells. Metastasis was evaluated macro- and microscopically in the left and right lobes of the lung separately in each mouse ( $n = 5$ ) (scale bar, 100  $\mu$ m). (D) Cell motility of HuH7 cells cocultured with HuH7, HLF, or HLF cells with imatinib mesylate (10  $\mu$ M) was monitored in a real-time manner by time-lapse image analysis. HuH7 and HLF cells were labeled with the lipophilic fluorescence tracer, Dil (indicated as red) or DiI (indicated as blue), and incubated in a  $\mu$ -Slide eight-well chamber overnight. Silicone inserts were detached and the culture media replaced with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, including 0.1% dimethyl sulfoxide (DMSO) (control) or 10  $\mu$ M of imatinib mesylate dissolved in DMSO (final concentration 0.1%). Immediately after the medium change, cells were cultured at 37°C in 5% CO<sub>2</sub> and time-lapse images were captured for 72 hours. (E) qPCR analysis of *TGFBI* in HuH7 (white bar), HLF (gray bar), and HLF cells pretreated with imatinib mesylate for 24 hours. (F) Smad3 and its phosphorylation evaluated by western blotting. HuH7 cells and HLF cells were harvested in cell culture inserts and treated with DMSO (0.1%) or imatinib mesylate (10  $\mu$ M) for 24 hours. Cell culture inserts were washed with PBS, cocultured with HuH7 cells for 8 hours, and then removed. HuH7 cells were lysed using radioimmunoprecipitation assay buffer for western blotting. (A) HuH7 cells cocultured with HuH7 cells. (B) HuH7 cells cocultured with HLF cells. (C) HuH7 cells cocultured with HLF cells pretreated with imatinib mesylate.

HBV X may play a role in generating EpCAM<sup>+</sup> CSCs.<sup>17</sup> The role of hepatitis virus infection on the generation of CSCs is still unclear and should be clarified in future studies.

We were unable to confirm the tumorigenicity of CD90<sup>+</sup> cells in 13 of 15 HCCs, but we observed abundant CD90<sup>+</sup> cells in more-advanced HCCs by IHC (data not shown). Tumorigenic CD90<sup>+</sup> cells may emerge at a later stage of hepatocarcinogenesis, and the majority of CD90<sup>+</sup> cells in early HCCs may be cancer-associated VECs without tumorigenic capacity. Furthermore, we identified tumorigenic CD90<sup>+</sup> cells only from HBV-related HCCs, and a recent study suggested that expression of CD90 was associated with HBV infection.<sup>16</sup> We could not detect the small population of CD90<sup>+</sup> HuH7 and Hep3B cells reported on by Yang et al. However, because we identified a small population of CD90<sup>+</sup> HuH7 cells after treatment with 5-FU (manuscript in preparation), it is conceivable that different cellular stress statuses may explain the observed differences between our findings and those of Yang et al.

The majority of CSC markers discovered thus far are almost identical to those found in healthy tissue stem cells or embryonic stem cells. However, with regard to the liver, the characteristics of healthy hepatic stem/progenitor cells isolated using different stem cell markers are currently under investigation. A recent article examined the characteristics of EpCAM<sup>+</sup> and CD90<sup>+</sup> oval cells isolated from 2-acetylaminofluorene/partial hepatectomy or D-galactosamine-treated rats.<sup>18</sup> Interestingly, EpCAM<sup>+</sup> and CD90<sup>+</sup> oval cells represent two distinct populations: The former expresses classical oval cell markers, such as AFP, OV-1, and cytokeratin-19 (CK-19), whereas the latter expresses desmin and alpha smooth muscle actin, but not AFP, OV-1, or CK-19, which indicates that CD90<sup>+</sup> populations are more likely to be mesenchymal cells. Another study has demonstrated that mesenchymal cells can interact with HSCs to regulate cell-fate decision.<sup>19</sup> We found that EpCAM<sup>+</sup> and CD90<sup>+</sup> cells isolated from liver cancer are distinct in terms of gene- and protein-expression patterns in both primary liver cancers and cell lines. Furthermore, these distinct CSCs can interact to regulate the tumorigenicity and metastasis of HCC. Molecular characteristics of EpCAM<sup>+</sup>/CD90<sup>+</sup> CSCs may potentially reflect the cellular context of healthy stem or progenitor cells.

Although our study strongly indicates that abundant CD90<sup>+</sup> cells in a tumor is a risk for distant metastasis in liver cancer, the cell identity and role of CD90<sup>+</sup> cells remains elusive. As our IHC, FACS, and xenotransplantation assays revealed, some CD90<sup>+</sup> cells in

liver cancer may be cancer-associated VECs or fibroblasts that cannot perpetuate in the xenograft. Recent findings have suggested the importance of stromal cells in tumorigenesis and cancer metastasis,<sup>20-22</sup> so it is possible that these cells may help TECs invade and intravasate into blood vessels, thus playing crucial roles in metastasis.

Another possibility is that CD90<sup>+</sup> cells are cancer cells with features of fibroblasts (having undergone EMT) or VECs (having undergone vasculogenic mimicry; VM) that can invade, intravasate, and metastasize cells to distant organs. Recently, two groups reported that a subset of tumor VECs originate from glioblastoma CSCs.<sup>23,24</sup> We successfully confirmed the tumorigenicity and metastatic capacity of CD90<sup>+</sup> cells that were morphologically identical to VECs from primary HCCs that could perpetuate in the xenograft. However, a recent study demonstrated that CD90<sup>+</sup> HCC cells express glypican-3, a marker detected in hepatic epithelial cells.<sup>25</sup> Further studies are warranted to clarify the nature and role of CD90<sup>+</sup> HCC cells.

In our study, CD90<sup>+</sup> cells expressed the endothelial marker, c-Kit, CD105, and VEGFR1, and a mesenchymal VEC morphology and high metastatic capacity were confirmed in both primary liver cancer and cell lines. We further confirmed that CD90<sup>+</sup> liver cancer cells showed chemosensitivity to imatinib mesylate, suggesting that cancer cells committed to mesenchymal endothelial lineages could be eradicated by the compound. Although imatinib mesylate treatment had little effect on the size of primary tumors originated from both EpCAM<sup>+</sup> and CD90<sup>+</sup> CSCs, it significantly suppressed lung metastasis *in vivo*. These data are consistent with a recent phase II study demonstrating the tolerable toxicity, but limited efficacy, of imatinib mesylate alone for unresectable HCC patients. Eligibility of imatinib mesylate for advanced HCC patients may be restricted to the HCC subtypes organized by CD90<sup>+</sup> CSCs with a highly metastatic capacity and VEC features. Therefore, a combination of compounds targeting EpCAM<sup>+</sup> tumorigenic CSCs as well as CD90<sup>+</sup> metastatic CSCs may be required for the eradication of HCC and should be tested in the future.

*Acknowledgments:* The authors thank Ms. Nami Nishiyama and Ms. Mikiko Nakamura for their excellent technical assistance.

## References

1. Tsai WL, Chung RT. Viral hepatocarcinogenesis. *Oncogene* 2010;29: 2309-2324.

2. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. *HEPATOLOGY* 2006;44:240-251.
3. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD133 is a therapeutic target in human liver cancer stem cells. *J Clin Invest* 2010;120:3326-3339.
4. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. *Cell Stem Cell* 2010;7:694-707.
5. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. *Cancer Cell* 2008;13:153-166.
6. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohta T, Nakanuma Y. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. *Am J Pathol* 2007;170:1750-1762.
7. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. *Cell Stem Cell* 2011;9:50-63.
8. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. *Cancer Res* 2007;67:10831-10839.
9. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Res* 2008;68:1451-1461.
10. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. *Gastroenterology* 2009;136:1012-1024.
11. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. *Gastroenterology* 2007;132:2542-2556.
12. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. *In Vitro Cell Dev Biol* 1992;28A:136-142.
13. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. *Cancer Cell* 2011;19:387-400.
14. Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. *Anticancer Drugs* 2004;15:405-409.
15. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. *HEPATOLOGY* 2011;54:1707-1717.
16. Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Hu RM. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. *Acta Histochem* 2011;113:833-838.
17. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? *Cancer Res* 2011;71:3701-3708.
18. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD. Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. *HEPATOLOGY* 2008;47:636-647.
19. Wang Y, Yao HL, Cui CB, Wauthier E, Barbier C, Costello MJ, et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates. *HEPATOLOGY* 2010;52:1443-1454.
20. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. *Crit Rev Oncol Hematol* 2009;69:108-124.
21. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* 2007;449:557-563.
22. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. *Cancer Res* 2008;68:4331-4339.
23. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* 2010;468:824-828.
24. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. *Nature* 2010;468:829-833.
25. Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu WC, et al. Gene expression profiling of liver cancer stem cells by RNA-sequencing. *PLoS One* 2012;7:e37159.

## Increase in CD14<sup>+</sup>HLA-DR<sup>-/low</sup> myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

Fumitaka Arihara · Eishiro Mizukoshi · Masaaki Kitahara · Yoshiko Takata · Kuniaki Arai · Tatsuya Yamashita · Yasunari Nakamoto · Shuichi Kaneko

Received: 15 February 2013 / Accepted: 29 May 2013 / Published online: 14 June 2013  
© Springer-Verlag Berlin Heidelberg 2013

**Abstract** Myeloid-derived suppressor cells (MDSCs) are known as key immune regulators in various human malignancies, and it is reported that CD14<sup>+</sup>HLA-DR<sup>-/low</sup> MDSCs are increased in hepatocellular carcinoma (HCC) patients. However, the host factors that regulate the frequency and the effect on the prognosis of HCC patients are still unclear. We investigated these issues and clarified the relationships between a feature of MDSCs and host factors in HCC patients. We examined the frequency of MDSCs in 123 HCC patients, 30 chronic liver disease patients without HCC, and 13 healthy controls by flow cytometric analysis. The relationships between the clinical features and the frequency of MDSCs were analyzed. In 33 patients who received curative radiofrequency ablation (RFA) therapy, we examined the impact of MDSCs on HCC recurrence. The frequency of MDSCs in HCC patients was significantly increased. It was correlated with tumor progression, but not with the degree of liver fibrosis and inflammation. In terms of serum cytokines, the concentrations of IL-10, IL-13, and vascular endothelial growth factor were significantly correlated with the frequency of MDSCs. In HCC patients who received curative RFA therapy, the

frequency of MDSCs after treatment showed various changes and was inversely correlated with recurrence-free survival time. The frequency of MDSCs is correlated with tumor progression, and this frequency after RFA is inversely correlated with the prognosis of HCC patients. Patients with a high frequency of MDSCs after RFA should be closely followed and the inhibition of MDSCs may improve the prognosis of patients.

**Keywords** Myeloid-derived suppressor cells · Hepatocellular carcinoma · Radiofrequency ablation · Recurrence · Cancer

### Abbreviations

MDSCs	Myeloid-derived suppressor cells
HCC	Hepatocellular carcinoma
CLD	Chronic liver disease
RFA	Radiofrequency ablation
TACE	Transcatheter arterial chemoembolization
PBMC	Peripheral blood mononuclear cell
Tregs	Regulatory T cells
HLA	Human leukocyte antigen
FGF	Fibroblast growth factor
CCL	Chemokine C–C motif ligand
G-CSF	Granulocyte colony stimulating factor
GM-CSF	Granulocyte macrophage colony stimulating factor
IP	Interferon gamma-induced protein
MCP	Monocyte chemoattractant protein
MIP	Macrophage inflammatory protein
PDGF	Platelet-derived growth factor
RANTES	Regulated upon activation, normal T cell expressed and secreted
TNF	Tumor necrosis factor
VEGF	Vascular endothelial growth factor

**Electronic supplementary material** The online version of this article (doi:10.1007/s00262-013-1447-1) contains supplementary material, which is available to authorized users.

F. Arihara (✉) · E. Mizukoshi · M. Kitahara · Y. Takata · K. Arai · T. Yamashita · S. Kaneko  
Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan  
e-mail: bnkyo78@gmail.com; arihara@m-kanazawa.jp

Y. Nakamoto  
Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Matsuoka, Fukui, Japan



JAK Janus kinase  
 STAT Signal transducer and activator of transcription

## Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer mortality globally [1, 2]. Current treatment options including surgical resection, radiofrequency ablation (RFA), liver transplantation, chemotherapy, transcatheter arterial chemoembolization (TACE), and sorafenib are reported to improve survival in HCC patients [3–7]. However, despite curative treatments for HCC, tumor recurrence rates remain high and the survival of those who have advanced HCC remains unsatisfactory [3–7]. Therefore, the development of new anti-tumor treatments for HCC remains an urgent and important field of research.

To overcome the limitations of these treatments, several immunotherapies have been developed as attractive strategies for HCC. In several studies of HCC immunotherapy, effective induction of immune-mediated cells by tumor antigen-derived peptides or antigen-presenting cells showed anti-tumor effects, but the population of patients who exhibited such effects was very small [8–12].

In previous studies, it was reported that many kinds of tumor generate a number of immune-suppressive mechanisms [13–15]. Recently, myeloid-derived suppressor cells (MDSCs) have been characterized as key immune regulators in various human cancers [15–24]. They show the capacity to inhibit T cell function and promote tumor development [15, 25]. Human MDSCs are a heterogeneous population that shows CD11b<sup>+</sup>, CD33<sup>+</sup>, HLA-DR<sup>-low</sup> and can be divided into granulocytic CD14<sup>-</sup> and monocytic CD14<sup>+</sup> subtypes [26–28]. In most recent studies, it has been reported that CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs were increased in HCC patients and the cells inhibited the function of T cells through the induction of regulatory T cells (Tregs) [24]. Tregs represent 5–10 % of CD4<sup>+</sup> T cells and can suppress the activation and proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells [14, 29]. It was reported that an increased frequency of circulating Tregs was associated with poor survival of HCC patients [30]. Understanding the inhibitory mechanism of MDSCs and controlling their function are very important to develop more effective immunotherapy for HCC.

In this study, we investigate the host factors that are associated with the frequency of MDSCs in HCC patients and the effect of MDSCs on the prognosis of patients and clarify the relationships between a feature of MDSCs and host factors in HCC patients.

## Materials and methods

### Patients and healthy controls

Blood samples were obtained from a total of 123 HCC patients, 26 chronic liver disease (CLD) patients without HCC, and 13 healthy controls. The diagnosis of HCC was histologically confirmed in 68 patients. For the remaining 55 patients, diagnosis was made by dynamic CT or MRI. Patient characteristics and disease classification are shown in Suppl. table 1. All CLD patients without HCC underwent percutaneous liver biopsy to evaluate the disease severity according to the Metavir scoring system. In 33 patients treated with curative percutaneous RFA, blood samples were obtained on the day of treatment and 2–4 weeks after treatment, and we observed recurrence of these patients with periodic imaging studies. All subjects provided written informed consent to participate in this study in accordance with the Declaration of Helsinki. This study was approved by the regional ethics committee (Medical Ethics Committee of Kanazawa University).

### Cell isolation and flow cytometric analysis

Peripheral blood mononuclear cells (PBMCs) were separated as described below; heparinized venous blood was diluted in phosphate-buffered saline (PBS) and loaded on Ficoll-Histopaque (Sigma, St. Louis, Mo.) in 50 ml tubes. After centrifugation at 2,000 rpm for 20 min at room temperature, PBMCs were harvested from the interphase, resuspended in PBS, centrifuged at 1,400 rpm for 10 min, and finally resuspended in complete culture medium consisting of RPMI (GibcoBRL, Grand Island, NY), 10 % heat inactivated FCS (Gibco BRL), 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco BRL). PBMCs were resuspended in RPMI 1,640 medium containing 80 % FCS and 10 % dimethyl sulfoxide and cryopreserved until use. The viability of cryopreserved PBMCs was 60–70 %. In some patients, fresh and cryopreserved PBMCs were obtained from the same sample. To determine the frequency and phenotype of MDSCs and Tregs, multicolor fluorescence-activated cell sorting analysis was carried out using the Becton–Dickinson FACSaria II system. The following anti-human monoclonal antibodies were used: anti-CD4 (Becton–Dickinson), anti-CD11b (Becton–Dickinson), anti-CD14 (Becton–Dickinson), anti-CD15 (Becton–Dickinson), anti-CD25 (Becton–Dickinson), anti-CD33 (Becton–Dickinson), anti-CD127 (Becton–Dickinson), and anti-HLA-DR (Becton–Dickinson).

### Suppression assay

CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs and CD14<sup>+</sup>HLA-DR<sup>+</sup> cells were sorted using the Becton–Dickinson FACSaria II

system.  $2 \times 10^4$  PBMCs were cultured and stimulated with 1  $\mu\text{g}/\text{ml}$  plate-bound anti-CD3 (eBioscience) and 1  $\mu\text{g}/\text{mL}$  soluble anti-CD28 (eBioscience) in 96-well round-bottomed plates. 24 h later, to determine the suppressive ability of MDSCs, increasing concentrations of MDSCs were added to the stimulated PBMCs. Proliferation was measured by  $^3\text{H}$  incorporation after 72 h. [ $^3\text{H}$ ] thymidine was added, and cell proliferation was measured by incorporation of radiolabeled thymidine for 24 h.

#### Cytokine and chemokine profiling

Blood samples were collected from patients at the same time of PBMC isolation. After centrifugation at 3,000 rpm for 10 min at 4 °C, serum fractions were obtained and stored at -20 °C until use. Serum levels of various cytokines and chemokines were measured using the Bio-Plex Protein Array System. Briefly, frozen serum samples were thawed at room temperature and diluted 1:4 in sample diluents; 50  $\mu\text{l}$  aliquots of the diluted sample was added in duplicate to the wells of 96-well microtiter plates containing the coated beads for a validated panel of human cytokines and chemokines according to the manufacturer's instructions. The following 27 cytokines and chemokines were targeted: IL-1 $\beta$ , IL-1 receptor antagonist (IL-1Ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, basic fibroblast growth factor (FGF), eotaxin (chemokine C-C motif ligand (CCL) 11), G-CSF, GM-CSF, IFN- $\gamma$ , interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1 $\alpha$ , MIP-1 $\beta$ , platelet-derived growth factor (PDGF)-BB, regulated upon activation, normal T cell expressed and secreted (RANTES), TNF- $\alpha$ , and vascular endothelial growth factor (VEGF). Nine standards (ranging from 0.5 to 32,000 pg/ml) were used to generate calibration curves for each cytokine. Data acquisition and analysis were performed using Bio-Plex Manager software version 4.1.1.

#### Statistical analysis

Data are expressed as the mean  $\pm$  SD. Chi-squared test with Yates' correction, unpaired *t* test, Mann–Whitney *U* test, and Kruskal–Wallis were used for univariate analysis of two groups that were classified according to the frequency of MDSCs. The probability of tumor recurrence-free survival was estimated using the Kaplan–Meier method. The Mantel–Cox log-rank test was used to compare curves between groups. The prognostic factors for tumor recurrence-free survival were analyzed for statistical significance by the Kaplan–Meier method (univariate) and the Cox proportional hazard model (multivariate). Variables with  $p < 0.1$  were entered into multivariate logistic

regression analysis. A level of  $p < 0.05$  was considered significant.

## Results


### CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs are increased in the peripheral blood of HCC patients

We analyzed the peripheral blood of 123 patients with HCC, 26 CLD patients without HCC, and 13 healthy donors for the prevalence of CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs. Because the PBMCs are tested after Ficoll, some cells may be lost. Therefore, we examined the population of MDSCs as a percentage of total CD14<sup>+</sup> cells by flow cytometry after cell surface labeling for the expression of HLA-DR (Fig. 1a). CD14<sup>+</sup>HLA-DR<sup>-low</sup> population in PBMCs of HCC patients represented 3.2–56.8 % of the CD14<sup>+</sup> cells. The frequency of CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs/CD14<sup>+</sup> cells in cryopreserved PBMCs correlated with that in fresh PBMCs (Fig. 1b). Therefore, we analyzed the frequency of CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs/CD14<sup>+</sup> cells using cryopreserved PBMCs.

To confirm the function of these cells, sorted CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs and CD14<sup>+</sup>HLA-DR<sup>+</sup> (control) cells were added at different ratios to autologous anti-CD3/CD28-stimulated PBMCs, and the proliferation was measured by  $^3\text{H}$  incorporation. CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs of HCC patients significantly decreased autologous PBMC proliferation (Fig. 1c). On the other hand, CD14<sup>+</sup>HLA-DR<sup>+</sup> (control) cells could not suppress the autologous PBMC proliferation.

As shown in Fig. 1d, the frequency of MDSCs was significantly higher in HCC patients (19.0 %) than in healthy donors (9.4 %) ( $p < 0.01$ ). Overall frequencies of CD14<sup>+</sup> cells did not differ significantly between the groups (Fig. 1e). Individual frequencies of MDSCs of all the patients and healthy donors are represented as scatter plots (Fig. 2a). The frequency of MDSCs was correlated with the stage of HCC (stage III and IV: 22.3 % ( $n = 46$ ) vs. stage I and II: 17.0 % ( $n = 77$ ),  $p < 0.01$ ) and was significantly higher in HCC patients than CLD patients without HCC and healthy donors. Interestingly, there was no difference between CLD patients without HCC and healthy donors. Moreover, these numbers did not change depending on the degree of fibrosis or inflammatory activity of the liver (Fig. 2b, c).

In previous reports, granulocytic MDSCs were defined in combination with several surface markers including CD14, CD15, CD11b, CD33, CD66b, and HLA-DR in several cancers. Therefore, we examined the frequency of CD15<sup>+</sup>CD14<sup>-</sup>CD11b<sup>+</sup>CD33<sup>+</sup> cells in 37 HCC patients and 11 healthy donors (Suppl. figure 1A). Although there was no statistical significant difference, the frequency of



**Fig. 1** a Flow cytometry shows CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs. PBMCs from patients and healthy donors were labeled with anti-CD14 and HLA-DR. Three staining examples of HCC patients are shown in the order from a small number (left) to a large number (right). b The increase in CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs/CD14<sup>+</sup> cells in cryopreserved PBMC correlated with that in fresh PBMC ( $r^2 = 0.52$ ). c Proliferation of PBMCs stimulated by anti-CD3/28 in

the presence or absence of MDSCs was measured by <sup>3</sup>H incorporation assay. CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs significantly decreased autologous PBMC proliferation ( $n = 4$ ; \*,  $p < 0.05$ ). d The frequency of MDSCs was significantly higher in HCC patients than healthy donors (\*,  $p < 0.01$ ). e Overall frequencies of CD14<sup>+</sup> cells did not differ significantly


CD15<sup>+</sup>CD14<sup>-</sup>CD11b<sup>+</sup>CD33<sup>+</sup> cells in HCC patients was higher than that in healthy donors (2.84 vs. 2.06 %,  $p = 0.073$ ) (Suppl. figure 1B). The frequency was correlated with the stage of HCC (stage III and IV: 3.69 % ( $n = 13$ ) vs. stage I and II: 2.39 % ( $n = 24$ ),  $p = 0.022$ ) (Suppl. figure 1C).

Relationship between the frequency of Tregs and MDSCs

It is well known that the frequency of circulating Tregs is increased and correlated with disease progression in HCC patients. The frequency of CD4<sup>+</sup> CD25<sup>+</sup> CD127<sup>-low</sup> Tregs was significantly increased in HCC patients (Suppl. figure 2A) and associated with tumor progression (Suppl. figure 2B). However, there was not a strong correlation between the frequency of MDSCs and Tregs in our study (Suppl. figure 2C).

Identification of host factors related to the frequency of MDSCs in HCC patients

We divided the HCC patients into two groups using the threshold of an MDSC ratio of 22 %. This threshold is the average +2SD of the MDSC ratio in non-HCC patients. In the group with high frequency, the tumor factors including size, multiplicity, and stage were significantly worse (tumor size, 28.3 vs. 24.4 mm; tumor multiplicity (multiple/solitary), 27/12 vs. 42/42; TNM stage (I and II vs. III and IV), 17/22 vs. 60/24,  $p < 0.05$ ) (Table 1). Moreover, hepatic reserve was also worse in the group with high frequency (Child-Pugh classification (A/B/C), 20/17/2 vs. 64/16/4,  $p < 0.05$ ). In addition, overall survival was significantly shortened in the group with high frequency (hazard ratio 2.67,  $p = 0.008$ ) (Suppl. figure 3A), and recurrence-free survival was also significantly shortened (hazard ratio 1.94,  $p = 0.010$ ) (Suppl. figure 3B).



**Fig. 2** a Scatter plots of MDSC ratio (CD14<sup>+</sup>HLA-DR<sup>-low</sup> MDSCs/CD14<sup>+</sup> cells) in patients and healthy donors. The frequency of MDSCs was significantly increased in HCC patients compared with that in non-HCC controls. Moreover, the frequency of MDSCs was correlated with tumor progression (stage III and IV: 22.3 % (*n* = 46)

vs. stage I and II: 17.0 % (*n* = 77); \*, *p* < 0.05). In non-HCC controls, there was no significant difference in the frequency of MDSCs. b, c In non-HCC patients, the frequency of MDSCs did not change depending on the degree of fibrosis or inflammatory activity of the liver according to the Metavir scoring system

Relationship between serum cytokine levels and the frequency of MDSCs

In previous studies, the balance of circulating cytokines was thought to promote accumulation and activation of MDSCs [18, 31–34]. Therefore, we examined the relationship between serum cytokine levels and the frequency of MDSCs in HCC patients. In 54 HCC patients, serum levels of cytokines and chemokines were measured using the Bio-Plex Protein Array system. Serum concentrations of IL-10, IL-13, and VEGF were significantly increased in the group with a high frequency of MDSCs (Table 2). In addition, there was a positive correlation between these cytokine levels in serum and the frequency of MDSCs. We also examined the relationship between serum cytokine levels and the frequency of Tregs. We divided the HCC patients into two groups using the threshold of 7 %, which is the average +2SD of the % of Tregs among CD4<sup>+</sup> cells in non-HCC patients. Serum concentration of IL-10 was significantly increased in the group with a high frequency of Tregs (Suppl. table 2).

Kinetics of MDSCs before and after curative RFA therapy

We examined the frequency of MDSCs before and after curative RFA therapy in 33 patients. For this analysis, blood samples were obtained on the day of treatment (before) and 2–4 weeks after treatment (after). The frequency of MDSCs was significantly decreased after RFA therapy (18.0 to 15.5 %, *p* < 0.05) (Fig. 3a). However, in several patients, the frequency of MDSCs remained at a high level compared with that in non-HCC patients. The clinical parameters before RFA were not statistically different between the patients with and without a high frequency of MDSCs after RFA (Suppl. table 3).

Next, we followed up these patients for recurrence and analyzed the risk factors. If a high frequency of MDSC was observed after curative RFA therapy, the recurrence-free survival was significantly shortened (Fig. 3b). In contrast, the frequency of MDSCs before treatment did not affect the recurrence. In univariate analysis for recurrence, post-treatment MDSC ratio ≥22 % (*p* = 0.023) and tumor